1. Inflammation is central to the pathogenesis of acute coronary syndrome (ACS) and is associated with adverse clinical outcomes after percutaneous coronary intervention (PCI). Recent in
vitro work has demonstrated the anti‐inflammatory effect of berberine, a primary component of the traditional Chinese medicine ‘umbellatine’. In the present study, we further tested whether berberine had any beneficial effects on ACS
patients following PCI.
2.In all, 130 ACS patients undergoing PCI were recruited to the present study. Sixty‐one patients were treated with berberine (300 mg, t.i.d., for 30 days) in addition to standard therapy,
whereas the remaining patients received standard therapy alone. Circulating inflammatory markers were measured by ELISA, whereas serum lipid profiles were measured by routine chemical assays.
3.In the berberine‐treated group, matrix metalloproteinase (MMP)‐9,
intercellular adhesion molecule (ICAM)‐1, vascular cell adhesion molecule (VCAM)‐1, C‐reactive protein, interleukin‐6 and monocyte chemoattractant protein‐1 were significantly reduced relative
to baseline values. Furthermore, the changes in MMP‐9, ICAM‐1 and VCAM‐1 from baseline to after 1 month of treatment differed significantly between the two patient groups. There was a tendency for berberine
to induce a slightly greater reduction in low‐density lipoprotein cholesterol and triglycerides than standard therapy alone, without affecting high‐density lipoprotein cholesterol, but the differences failed to reach statistical significance. No severe adverse effects of berberine
4.The results of the present study provide the first clinical evidence of the anti‐inflammatory action of berberine in ACS patients following PCI. Berberine may become adjunct therapy to further improve clinical outcomes via
its anti‐inflammatory effect in ACS patients.
No Supplementary Data
No Article Media
Document Type: Research Article
Publication date: May 1, 2012